After his presentation at the Nevada Psychopharmacology Course, Dr. Earley was interviewed by Clinical Psychiatry News. Medications are taking a more central role in the treatment of all types of addictive diseases, but especially in the treatment of Opioid Dependence. "What is important here is that there is no 'One size fits All' in medications for opioid dependence," Dr. Earley asserts. Take a moment and read the nice synopsis of the issues in medication management of Opioid Dependence by clicking here.
While combing through our archives, we came across two important interviews with Dr. Paul Earley. These interviews are extracted from hour-long specials produced by ABC news in the 1990s. Despite the fact that these interviews are about 15 years old, they provide important insights about heroin addiction. We hope you find them helpful. The first interview is from Hooked: from Hollywood to Main Street. Click here for Dr. Earley’s interview from Hooked: from Hollywood to Main Street.
The second interview is from Heroin: The New High School High. Click here for Dr. Earley’s interview from Heroin: The New High School High.
The latest designer drug to hit the United States is the compound Methylenedioxypyrovalerone (MDPV) marketed in the United States commonly as "bath salts." It is sold under many names in the southern part of the US (where we are), including "Ivory Wave" or "Purple Wave." It is sold in drug paraphernalia stores (head shops) but is commonly available in gas station markets and adult novelty stores. It is easily obtained and extremely dangerous.
What is MDPV? MDPV belongs to a category of drugs called cathinones. One natural souce of cathinones is from the drug khat, a dried plant derivative native to tropical East Africa and the Arabian Peninsula. Although related to more benign drugs, MDPV has several alarming properties.
On the 12th of October 2010, the FDA has approved another tool for the treatment of opioid dependence: injectable naltrexone. Here are several links about this important development: FDA Press Release, CNN First Story.Vivitrol is the brand name for the injectable naltrexone approved by the FDA for the treatment of opioid dependence.
We have been using this medication for over two years in the treatment of opioid (narcotic) dependence and feel like it is an excellent medication for the right person. Up until today, this use has been "off label" meaning that the FDA did not directly endorse its efficacy in opioid dependence (it was previously FDA approved only for alcohol dependence).Error contacting server